⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3287150 | 0.58 | — | — | |
| SCHEMBL136728 | 0.55 | — | — | |
| SCHEMBL3634636 | 0.55 | — | — | |
| Selenium SCHEMBL296728 | 0.47 | — | — | |
| SCHEMBL10895258 | 0.41 | — | — | |
| SCHEMBL6559802 | 0.41 | — | — | |
| SCHEMBL8331638 | 0.41 | — | — | |
| SCHEMBL23694 | 0.41 | — | — | |
| SCHEMBL3386 | 0.41 | — | — | |
| SCHEMBL7868197 | 0.41 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | claimed |
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | ABBVIE INC. (US) | 2015-02-26 | — | — | US | claimed |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC. (US) | 2014-08-21 | — | — | US | claimed |
| EP-2725015-A1 | Uracil or thymine derivative for treating hepatitis c | AbbVie Bahamas Ltd. (BS) | 2014-04-30 | — | — | EP | claimed |
| EP-2548873-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | Abbott Laboratories (US) | 2013-01-23 | — | — | EP | claimed |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | claimed |
| EP-2411352-A2 | ANTIVIRAL COMPOUNDS AND USES THEREOF | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | claimed |
| EP-2377854-A1 | N-phenyl-dioxo-hydropyrimidines useful as hepatitis C virus (HCV) inhibitors | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | claimed |
| EP-2203430-B1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | ABBOTT LAB (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010111436-A2 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | claimed |
| EP-2222646-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | claimed |
| EP-2203430-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | claimed |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | claimed |
| WO-2009039135-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | claimed |
| WO-2009039127-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | claimed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| WO-2005056568-A1 | FERROCENYL-1, 2-DIPHOSPHINES, THE PRODUCTION THEREOF AND THEIR USE | SOLVIAS AG (CH) | 2005-06-23 | — | — | WO | disclosed |
| US-20040230006-A1 | Use of a metallic mercaptothiazole or metallic mercaptobenzothiazole in golf ball compositions | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2004-11-18 | — | — | US | disclosed |
| US-20040230005-A1 | Use of a metallic mercaptothiazole or metallic mercaptobenzothiazole in golf ball compositions | ACUSHNET COMPANY | 2004-11-18 | — | — | US | disclosed |